Literature DB >> 25533778

Future Costs, Fixed Healthcare Budgets, and the Decision Rules of Cost-Effectiveness Analysis.

Pieter van Baal1, David Meltzer2, Werner Brouwer1.   

Abstract

Life-saving medical technologies result in additional demand for health care due to increased life expectancy. However, most economic evaluations do not include all medical costs that may result from this additional demand in health care and include only future costs of related illnesses. Although there has been much debate regarding the question to which extent future costs should be included from a societal perspective, the appropriate role of future medical costs in the widely adopted but more narrow healthcare perspective has been neglected. Using a theoretical model, we demonstrate that optimal decision rules for cost-effectiveness analyses assuming fixed healthcare budgets dictate that future costs of both related and unrelated medical care should be included. Practical relevance of including the costs of future unrelated medical care is illustrated using the example of transcatheter aortic valve implantation. Our findings suggest that guidelines should prescribe inclusion of these costs.
Copyright © 2014 John Wiley & Sons, Ltd.

Keywords:  decision rules; economic evaluation; future costs

Mesh:

Year:  2014        PMID: 25533778     DOI: 10.1002/hec.3138

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  20 in total

1.  From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare.

Authors:  Matthijs Versteegh; Saskia Knies; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2016-11       Impact factor: 4.981

2.  Future unrelated medical costs need to be considered in cost effectiveness analysis.

Authors:  Pieter van Baal; Alec Morton; David Meltzer; Werner Brouwer
Journal:  Eur J Health Econ       Date:  2019-02

3.  After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?

Authors:  Mark Sculpher; Stephen Palmer
Journal:  Pharmacoeconomics       Date:  2020-03       Impact factor: 4.981

4.  Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients.

Authors:  Michelle Tew; Philip Clarke; Karin Thursky; Kim Dalziel
Journal:  Pharmacoeconomics       Date:  2019-07       Impact factor: 4.981

5.  A framework for the estimation of treatment costs of cardiovascular conditions in the presence of disease transition.

Authors:  Mohit Goswami; Yash Daultani; Sanjoy Kumar Paul; Saurabh Pratap
Journal:  Ann Oper Res       Date:  2022-08-23       Impact factor: 4.820

6.  How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis.

Authors:  Laura Bojke; Andrea Manca; Miqdad Asaria; Ronan Mahon; Shijie Ren; Stephen Palmer
Journal:  Pharmacoeconomics       Date:  2017-08       Impact factor: 4.981

7.  How much might a society spend on life-saving interventions at different ages while remaining cost-effective? A case study in a country with detailed data.

Authors:  Giorgi Kvizhinadze; Nick Wilson; Nisha Nair; Melissa McLeod; Tony Blakely
Journal:  Popul Health Metr       Date:  2015-07-08

8.  Cost-effectiveness of population-based, community, workplace and individual policies for diabetes prevention in the UK.

Authors:  P R Breeze; C Thomas; H Squires; A Brennan; C Greaves; P Diggle; E Brunner; A Tabak; L Preston; J Chilcott
Journal:  Diabet Med       Date:  2017-04-18       Impact factor: 4.359

Review 9.  Systematic review of model-based economic evaluations of heart valve implantations.

Authors:  Simone A Huygens; Johanna J M Takkenberg; Maureen P M H Rutten-van Mölken
Journal:  Eur J Health Econ       Date:  2017-03-06

10.  Health, Health Inequality, and Cost Impacts of Annual Increases in Tobacco Tax: Multistate Life Table Modeling in New Zealand.

Authors:  Tony Blakely; Linda J Cobiac; Christine L Cleghorn; Amber L Pearson; Frederieke S van der Deen; Giorgi Kvizhinadze; Nhung Nghiem; Melissa McLeod; Nick Wilson
Journal:  PLoS Med       Date:  2015-07-28       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.